Short Interest in Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Drops By 69.0%

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) saw a significant drop in short interest in the month of June. As of June 30th, there was short interest totaling 14,925 shares, a drop of 69.0% from the June 15th total of 48,137 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 628,782 shares, the days-to-cover ratio is presently 0.0 days.

Daiichi Sankyo Stock Down 2.2%

DSNKY traded down $0.38 during trading on Monday, hitting $16.71. The company had a trading volume of 44,323 shares, compared to its average volume of 407,482. The company has a market capitalization of $31.13 billion, a PE ratio of 17.78, a PEG ratio of 2.94 and a beta of -0.17. Daiichi Sankyo has a one year low of $14.98 and a one year high of $27.50. The firm’s 50-day moving average price is $16.34 and its 200 day moving average price is $18.19. The company has a quick ratio of 1.64, a current ratio of 2.42 and a debt-to-equity ratio of 0.18.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.The firm had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities analysts expect that Daiichi Sankyo will post 0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Daiichi Sankyo has a consensus rating of “Hold”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.